Develops insight-driven business solutions designed to accelerate value by helping confidential clients in global biotech, IVD and life science industry gain strategic insights needed to identify and accelerate the development and commercialization of promising genomic and precision diagnostic solutions

Mentors and acts as sounding board for CEO and staff. Focus on healthcare DE&I• Crafted Health Equity #InclusionPledge B2B strategy and content for healthcare industry resulting in 4x funds• Member Board of Directors Strategic and Marketing subcommittees

Advises on new business model and go-to-market strategy for precision oncology, digital patient engagement health tech start-up. Translates patient, community, market and competitive insights into positioning, value propositions, segmentation strategy, tactics and messages for investors, B2B, HCP, KOLs, patients and care partners

• Created 4-phase business development strategy inclusive of organic growth framework• Identified then communicated capabilities and differentiators by crafting new brand positioning, messages, segmented collateral, focused social media and digital marketing strategy

Consultant transitioned to full-time.Solutions creation, integration and marketing for pharma services organization focused on oncology and specialty/rare disease product commercializationGuided corporate identity and repositioningDirected omnichannel and mixed media function HCP focused projects for pharmaceutical and diagnostic clients across therapeutic areas Led Academy of Oncology Nurse Navigators (AONN+) marketing

maternal fetal medicine, obstetrics, family/general practitioners, patient advocacy, patient customer baseLed marketing launch planning for first-in-indication, AI-driven, multi-analyte rule-out test for preeclampsiaDeveloped brand position and value proposition Drove patient advocacy organization partnership and DTC strategy

Full-time, then consultant due to COVID.Drove public relations, and strategic and tactical HCP, advocacy and patient marketing for new testing category Delivered month over month growth for DCISionRT through introduction of refined messaging and channelsDeveloped first corporate publication plan and associated PR, KOL and marketing plans, and CRM

Led company communications, strategic and tactical cross brand initiatives and marketing. Global breast medical and surgical oncology, patient advocacy and patient customer base Cross-functionally developed and launched new positioning and messaging to leverage strength of combined product offering of MammaPrint (FDA cleared) and BluePrint (LDT) in early-stage breast cancerDirected product strategy and marketing plans for portfolioLed Strategic Initiatives working group with intent to transform short- and long-term business modelSupported network of global distributors

Led strategic, tactical, analytical marketing activities in support of 2 proprietary oncology diagnostics and commercial team. Medical and surgical oncology, pathology, advocacy, patient customer base Initiated market creation plan inclusive of celebrity campaign to optimize sales and patient asks for rebranded, repositioned, relaunched proprietary Breast Cancer IndexBuilt market segmentation and deployed cost-effective tools and non-personal promotion tactics for physician audiences in early breast cancer and metastatic unknown primaryLed cross-functional KOL development strategy resulting in 170% of stated objectives

Led market and product preparation for proprietary, value-based diagnostics. Hematology/oncology, pathology and pharmaceutical discovery/development customer segments Branded and commercially introduced proprietary multiplexing platform, MultiOmyx, for the clinic and B2B. Still in market today for pharma discovery, product development with NeoGenomics.Introduced integrated tollgate product development and launch preparation process to newly acquired organization Defined, developed and launched first-in-class lab developed, high-value, proof-of-concept diagnostic test for pharma services, Hodgkin Lymphoma Profile by MultiOmyxAssessed cross-category portfolio for organic inorganic product development to deliver integrated value proposition in solid tumors as member GE Healthcare Precision Diagnostics Council

Responsible for all oncology products and product lifecycle team leadership. Medical and surgical oncology and pathology customer base Re-positioned, re-branded and re-launched immuno-oncology, buy & bill therapeutic, Proleukin, for metastatic melanoma and renal cell carcinomaLaunched 3 new, high-value, microRNA oncology diagnostics for Cancer of Unknown Primary, Non-Small Cell Lung Cancer (NSCLC) and Mesothelioma Executed watershed event with treated patient survivors of metastatic disease as kick-off to ambassador campaign

Retained after acquisition of Ligand Pharmaceuticals. Responsible for growing orphan indication 3 product portfolio. Medical and hematology oncology customer base. Guided cross-functional team to complete launch planning for NSCLC indication including scenario forecasting, strategic and tactical plan, competitive analysis, advisory boards, KOL identification and developmentIncreased sales and share for 2 products (ONTAK, Targretin capsules) in response to competitive launch in cutaneous T-cell lymphoma

Directed all marketing activities for $700M prostate cancer treatment, and $250M gynecology market. Formulated strategic direction for Lupron brands (buy & bill) to include life cycle management, new formulation/ dose launches, KOL development, physician education and promotion.Achieved 75% market share through refined positioning, segmentation, message creation and rep trainingPrior to corporate marketing role - specialty HCP and institutional sales territory and account management, managed markets marketing, oncology/women’s health sales territory management